Update on lymphatic mapping and sentinel node biopsy in the management of patients with melanocytic tumours

被引:36
作者
Cochran, AJ
Roberts, A
Wen, DR
Huang, RR
Itakura, E
Luo, F
Binder, SW
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA USA
[2] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA USA
[3] Jonsson Comprehens Canc Ctr, Los Angeles, CA 90034 USA
关键词
melanoma; sentinel nodes; microscopy; molecular biology; micrometastases; prognosis;
D O I
10.1080/00313020412331282726
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Aims: To communicate best practices for sentinel lymph node evaluation and assessment of prognosis for patients with melanoma. Methods: Description and justification of approaches derive from experience with management of more than 2000 melanoma patients evaluated by lymphatic mapping and sentinel node biopsy (LMSNB). Results: Pathologists, by detecting blue dye or carbon particles or alterations in nodal cell populations should attempt to confirm that a node submitted as sentinel is truly sentinel. Pathologists must adequately sample the node by examining multiple tissue sections and determine the presence or absence of metastatic melanoma using sections stained by H&E and immunocytochemistry. Approximately 20% of patients have melanoma in the sentinel node (SN) and accurate evaluation of SN tumour status is the most precise technique for staging clinically localised cutaneous melanoma. The remaining non-sentinel nodes (NSN) in the basin are tumour-free in 67% of patients with melanoma in the SN. Breslow thickness of the primary, the area of tumour in the SN (relative to total nodal area) and density of dendritic leukocytes in the SN paracortex (factors that are combinable in prognostic algorithms) predict metastases in the NSN and the likelihood of recurrence and melanoma-specific death. Conclusions: Careful pathological analysis is essential to determine the presence or absence of metastatic melanoma in sentinel nodes, findings that indicate whether completion lymphadenectomy is required. Quantitative analysis of the primary melanoma and the amount of tumour in the sentinel node, with evaluation of the dendritic cells in that node, provide invaluable information that predicts non-sentinel node tumour status with increased accuracy and the likelihood of future recurrence and death from melanoma. While these activities require considerable effort from pathologists, their clinical impact justifies the increased workload.
引用
收藏
页码:478 / 484
页数:7
相关论文
共 31 条
[1]   Nodal nevi and cutaneous melanomas [J].
Carson, KF ;
Wen, DR ;
Li, PX ;
Lana, AMA ;
Bailly, C ;
Morton, DL ;
Cochran, AJ .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1996, 20 (07) :834-840
[2]   Surgical pathology remains pivotal in the evaluation of 'sentinel' lymph nodes [J].
Cochran, AJ .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1999, 23 (10) :1169-1172
[3]   Optimized assessment of sentinel lymph nodes for metastatic melanoma: Implications for regional surgery and overall treatment planning [J].
Cochran, AJ ;
Roberts, A ;
Wen, DR ;
Huang, RR ;
Itakura, E ;
Luo, F ;
Binder, SW .
ANNALS OF SURGICAL ONCOLOGY, 2004, 11 (03) :156S-161S
[4]   Prediction of metastatic melanoma in nonsentinel nodes and clinical outcome based on the primary melanoma and the sentinel node [J].
Cochran, AJ ;
Wen, DR ;
Huang, RR ;
Wang, HJ ;
Elashoff, R ;
Morton, DL .
MODERN PATHOLOGY, 2004, 17 (07) :747-755
[5]   HISTOMORPHOMETRY IN THE ASSESSMENT OF PROGNOSIS IN STAGE-II MALIGNANT-MELANOMA [J].
COCHRAN, AJ ;
LANA, AMA ;
WEN, DR .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1989, 13 (07) :600-604
[6]   Sentinel lymph nodes show profound downregulation of antigen-presenting cells of the paracortex: Implications for tumor biology and treatment [J].
Cochran, AJ ;
Morton, DL ;
Stern, S ;
Lana, AMA ;
Essner, R ;
Wen, DR .
MODERN PATHOLOGY, 2001, 14 (06) :604-608
[7]  
COCHRAN AJ, 1987, J NATL CANCER I, V78, P399
[8]   The pathologist's role in sentinel lymph node evaluation [J].
Cochran, AJ .
SEMINARS IN NUCLEAR MEDICINE, 2000, 30 (01) :11-17
[9]  
COCHRAN AJ, 2000, MODERN PATHOL, V13, P61
[10]  
COCHRAN AJ, 2001, PROGR PATHOLOGY, V5, P45